Eyegate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapeutics and drug delivery systems for treating eye diseases. The company is developing EGP-437 that has completed Phase III clinical trials in anterior uveitis for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It is also developing Eyegate II drug delivery system. Eyegate Pharmaceuticals, Inc. is based in Waltham, Massachusetts.
Eyegate Pharmaceuticals Inc. (EYEG) Stock Research Links